Drupal.behaviors.print = function(context) {window.print();window.close();}>
Santaris Pharma, Exiqon, MD Anderson Cancer Center, Isis Pharmaceuticals, Alnylam, Takeda Pharmaceutical
May 29, 2008
Santaris Pharma, Exiqon, MD Anderson Cancer Center, Isis Pharmaceuticals, Alnylam, Takeda Pharmaceutical
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Regulus Selects HCV Drug Candidate, Will Develop without Partner GSK
May 16, 2013 / Gene Silencing News
Scripps, Novartis Team Uncovers New Details of Guide RNA, Argonaute2 Interaction
May 16, 2013 / Gene Silencing News
Gradalis Releases New Clinical Data on Cancer Vaccine
May 16, 2013 / Gene Silencing News
Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News
Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News